HOME >> BIOLOGY >> NEWS
Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies

ATLANTA -- Medroxyprogesterone acetate (MPA), a synthetic form of the naturally occurring steroid hormone progesterone widely used in contraceptives and hormone replacement therapy (HRT), increases aggression and anxiety and reduces sexual activity in female monkeys, according to a study published in the June edition of The Journal of Clinical Endocrinology and Metabolism. The investigators, from the Yerkes National Primate Research Center of Emory University and the Center for Behavioral Neuroscience (CBN) in Atlanta, say the findings may explain anecdotal reports of mood changes, depression and loss of libido in some women who use MPA for contraception and HRT.

In the counter balanced-designed study, Yerkes and CBN post-doctoral fellow Karen Pazol, PhD, compared aggression, anxiety and sexual behavior in six female pigtail macaques that received one week each of three different treatments: estrogen only, estrogen plus natural progesterone, and estrogen plus MPA.

Monkeys displayed significantly more aggressive and anxious behaviors when they received the estrogen/MPA combination as compared to when they received the estrogen only or the estrogen/progesterone combination. Dr. Pazol also noted a marked reduction in sexual activity during the estrogen/MPA treatment period.

"Our findings suggest MPA may be affecting certain neuroendocrine systems in a very different way than natural progesterone," explained Dr. Pazol. "In comparison to natural progesterone, MPA binds to glucocorticoid receptors with a much higher affinity and may have a greater impact on the brain's stress system."

Moreover, according to Dr. Pazol, unlike natural progesterone, MPA cannot be converted to the mood-regulating chemical, allopregnanolone. Changes in allopregnanolone levels have been associated with depression, anxiety disorders and premenstrual mood disorders in humans.

To identify MPA's behavioral e
'"/>

Contact: Kelly Thompson
kthomp8@emory.edu
404-727-9254
Emory University Health Sciences Center
7-Jun-2004


Page: 1 2

Related biology news :

1. Synthetic antifreeze could prevent ice growth
2. Synthetic clay could assist radioactive waste cleanup
3. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
4. Synthetic Lock Binds Some Molecules, Excludes Others
5. A Synthetic Peptide Destroys Brain Plaque Implicated in Alzheimers Disease
6. Cellular Engineers Design Custom Cell Surfaces Able To Adhere To Synthetic Materials
7. Synthetic Vitamin E And Natural Vitamin E Are Equally Powerful Antioxidents
8. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
9. Excess thyroid hormone harmful to fetus
10. Blood pressure hormone may inhibit growth of lung cancer
11. Hunt for a new plant hormone points to carotenoids

Post Your Comments:
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Md. , March 30, 2015  Spherix ... company committed to the fostering and monetization of ... v. VTech,  Case No. 3:13-cv-03494-M and  Spherix v. ... United States District Court for the Northern District ... update regarding Spherix v. Verizon, Case ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: